Free Newsletter
Register for our Free Newsletters
Access Control
Deutsche Zone (German Zone)
Education, Training and Professional Services
Government Programmes
Guarding, Equipment and Enforcement
Industrial Computing Security
IT Security
Physical Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec

Homeland Security designation for powder screening kit

20/20 BioResponse : 17 October, 2007  (New Product)
Powder testing pack can be used by emergency services for testing powders for presence of bio-terrorism agents such as anthrax or ricin.
The BioCheck Powdered Screening Test Kit, a product of 20/20 BioResponse has earned designation as a Qualified Anti-Terrorism Technology under the US Department of Homeland Security (DHS)'s SAFETY Act .

The SAFETY (Support Anti-terrorism by Fostering Effective Technologies) Act encourages the development and rapid deployment of anti-terrorism technologies by giving buyers and sellers of qualified technologies liability protection from lawsuits. This effectively protects 20/20, as well as its customers and resellers, from the consequences of litigation arising from the use of the designated product in a terrorist incident.

"This designation is an important milestone for our company and our BioCheck customers," said Jerry Troy, Vice President of 20/20 BioResponse. "In addition to validating the safety and efficacy of the product, based on an extensive DHS review that spanned several months, it helps guard our customers and distributors against lawsuits that could follow an act of bioterrorism."

The BioCheck Kit is a market leader in the screening of suspicious powders and is used by more than 500 first responder organizations worldwide. Users include fire departments in major jurisdictions and more than a dozen US federal agencies. The kit provides a rapid screen to rule out the presence of multiple bio-terrorism agents (eg anthrax, ricin, botulism toxin) in suspicious powders. The product requires no instrumentation and helps first responders determine in five minutes or less whether testing for one or more specific pathogens or toxins is warranted. The novel technology in the BioCheck Kit is protected by two US patents.

20/20 BioResponse develops biotechnology solutions for first responders. It is a unit of 20/20 GeneSystems that focuses on innovative diagnostics products for cancer and other medical applications. The company is privately held and headquartered in Rockville, Maryland.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo